A study showed that small nucleotide polymorphisms within YTHDC2 and FTO are significantly correlated to the prognosis of patients with HCC treated with TACE, suggesting that they may be potential targets to enhance treatment approaches for patients with unresectable HCC [157]. Here, YTHDC2 is linked to hepatocellular carcinoma.